ATGAM General Investigation
← catalyst calendarNCT06039020 · readout in 156 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-21 | actual | When the study began enrolling |
| Primary completion | 2027-01-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-22 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Aplastic Anemia
Intervention
- Drug: Anti-human thymocyte immunoglobulin, equine
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse drug reactions (ADRs)
measured 24 weeks (6 months) from the start of administration (Day 1)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed